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Complement receptor type 1 (CR1) plays a central role in clearing immune complexes from the circulation and
probably contributes to the retention of immune complexes on the surface of follicular dendritic cells. Virus-specific,
complement-activating antibodies can target human immunodeficiency virus type 1 (HIV-1) to CR1-bearing cells but
the potential impact that these antibodies have on HIV-1 pathogenesis is unknown. To study these antibodies, an
assay was developed in which immune complexes containing HIV-1, antibody, and complement were formed in vitro
and captured on the surface of 96-well immunoplates coated with recombinant soluble human CR1 (rsCR1). Captured
virus was detected by p24 immunoassay or by infection of human CD4/ lymphocytes. Two laboratory strains of HIV-
1 (IIIB and MN) and primary isolates could be captured using sera from infected individuals or vaccinated volunteers
as a source of complement-activating antibodies. HIV-1 immune complexes captured by solid-phase rsCR1 could
be transferred to MT-2 cells for productive infection. Antibodies had no activity in this assay when the normal human
serum used as a source of complement had been heat-inactivated or depleted of complement component C3,
confirming a requirement for complement. These complement-activating antibodies in sera from infected individuals
showed strong cross-reactivity with HIV-1 IIIB, MN, and a heterologous primary isolate, but reacted poorly with the
autologous isolate obtained at the time of serum collection. Average titers of these antibodies measured with HIV-
1 IIIB were moderately lower in HIV-1-infected progressors compared to nonprogressors. In contrast to sera from
infected individuals, sera from gp160IIIB-vaccinated volunteers showed specificity for the vaccine strain of virus.
These results provide supporting evidence that envelope-specific, complement-activating antibodies induced by
infection or gp160 immunization can target HIV-1 immune complexes to CR1. In addition, they demonstrate that
such antibodies may sometimes be type-specific and that HIV-1 immune complexes bound to CR1 are infectious.
q 1996 Academic Press, Inc.
INTRODUCTION source of antigen for generating immune responses to
infection (Tew and Mandel, 1978; Jacob et al., 1991).
Complement receptor type 1 (CR1, CD35) is a recep-
Human immunodeficiency virus type 1 (HIV-1) activatestor for particulate antigens coated with C3b and iC3b
complement through epitopes in its surface gp120 andfragments of complement component C3 (Ross and
transmembrane gp41 envelope glycoproteins (Soelder etMedof, 1985; Muller-Eberhard, 1988). The receptor is
al., 1989; Ebenbichler et al., 1991; Marschang et al., 1993;found on red blood cells (RBC), follicular dendritic cells
Thieblemont et al., 1993b; Stoiber et al., 1994; Susal et al.,(FDC), monocytes, macrophages, neutrophils, eosino-
1994; Thielens et al., 1993). Complement activation by HIV-phils, B lymphocytes, and glomerular podocytes
1 is dramatically increased when envelope-specific anti-(Fearon, 1980; Wilson et al., 1983; Reynes et al., 1985).
bodies are present (Robinson et al., 1990, 1991; MontefioriRBC account for 90 – 95% of CR1 in circulation, where
et al., 1992a,b). Complement activation by HIV-1 does notit assists in transporting immune complexes to the liver
lead to virus destruction by the membrane attack complexand spleen for destruction by fixed macrophages (Nel-
of the terminal complement pathway (Harada et al., 1985;son, 1953; Cornacoff et al., 1983; Ross and Medof,
Banapour et al., 1986), which may be due to the presence1985; Herbert and Cosio, 1987; Rosse, 1987; Schifferli
of one or more complement control proteins on the viruset al., 1988). CR1 may also contribute to the retention
surface (Montefiori et al., 1994; Marschang et al., 1995;of immune complexes on the surface of follicular den-
Saifuddin et al., 1995; Stoiber et al., 1996). Complement-dritic cells, where immune complexes serve as a
opsonized HIV-1 is therefore free to interact with comple-
ment receptors on multiple cell types that could influence
1 To whom correspondence and reprint requests should be ad- HIV-1 pathogenesis in a number of different ways (Montefi-
dressed at Department of Surgery, Duke University Medical Center,
ori, 1996, review).P.O. Box 2926, Durham, NC 27710. Fax: (919) 684-4288. E-mail: mon
te005@mc.duke.edu. We previously determined that complement-activating
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antibodies can target HIV-1 immune complexes to CR1 Pont). Clinical information on the progressors P59423,
W25798, V89872, V67970, W179273, and W86165 mayexpressed on the surface of transfected K562 cells and
red blood cells (Montefiori et al., 1994). Genetically engi- be found in a previous report (Montefiori et al., 1996).
Progressors studied here and who were not describedneered, recombinant soluble CR1 (rsCR1) has properties
that are shared with the native molecule (Klickstein et previously include M35064 (50 CD4/ cells/mm3), W08684
(108 CD4/ cells/mm3), W35323 (10 CD4/ cells/mm3),al., 1988; Weisman et al., 1990), and here we show that
HIV-1 immune complexes may be captured by rsCR1 on and W44991 (10 CD4/ cells/mm3), all of whom had one
or more opportunistic infections. Other progressors nota solid support. The model was used to demonstrate that
complement-activating antibodies which target HIV-1 to described previously included C78104 and D75899, who
had 312 and 90 CD4/ cells/mm3, respectively, but wereCR1 are sometimes type specific and that virus captured
by solid-phase rsCR1 is infectious. otherwise asymptomatic. Four additional HIV-1-infected
individuals were included in these studies for whom no
clinical information was available (S69160, S68030,MATERIALS AND METHODS
T00953, and S23076). All individuals signed appropriate
Virus stocks consent forms as approved by local institutional review
boards. Human sera used as a source of complete com-Stocks of HIV-1 strains IIIB and MN were prepared in
plement or C3-deficient complement were obtained ly-cultures of H9 cells maintained in RPMI 1640 containing
ophilized from Sigma (St. Louis, MO). Sera used as12% heat-inactivated fetal bovine serum and 50 mg genta-
sources of complement and as antibody-negative con-micin/ml (Montefiori et al., 1988). Primary isolates were
trols were confirmed to be HIV-1-negative by Westernobtained from peripheral blood mononuclear cells
immunoblot (DuPont).(PBMC) of infected individuals by co-culturing their
PBMC with phytohemagglutinin (PHA)-stimulated PBMC
Capture of HIV-1 immune complexes by solid-phasefrom healthy, noninfected individuals as described pre-
rsCR1 (CR1-IC assay)viously (Montefiori et al., 1996). Virus-containing culture
fluids were made cell-free by 0.45 mm filtration and stored
Nunc 96-well immunoplates (MaxiSorp F96) werein aliquots at 0707. Total p24 content was quantified by
coated with rsCR1 (T Cell Sciences, Needham, MA) byp24 immunoassay (Organon-Teknika/Akzo, Durham, NC)
adding 100 ml of rsCR1 (2 mg/ml) in carbonate buffer, pHafter disruption of virus particles in 0.5% Triton X-100.
9.8, to each well and incubating the plates at 377 for 1All virus stocks contained less than 15% free p24 as
hr and then at 47 overnight. The rsCR1 solution was aspi-determined by immunoassay on nondisrupted virions.
rated and the wells were washed once with 200 ml of
PBS. Wells were then filled with 200 ml of blocking solu-Human sera
tion (PBS containing 1% bovine serum albumin, pH 7.4),
incubated at 377 for 90 min, and washed 31 with 200 mlPeripheral blood that was free of preservatives and
anticoagulants was obtained from noninfected individu- of sterile carbonate buffer containing 0.05% Tween 20.
Test sera were diluted in growth medium and 25 ml ofals, vaccinated volunteers, and HIV-1-infected individuals
who were either nonprogressors (infected ⁄2 years, each dilution was added to wells containing 25 ml of
fresh normal human serum as a source of complement.asymptomatic, CD4/ cells 600/mm3) or progressors
(CD4/ cells 380/mm3). Blood was allowed to coagulate Cell-free virus (50 ml) was added to each well and the
plates were incubated at 377 for 3 hr to allow for comple-at room temperature and the serum was collected after
centrifugation, heat-inactivated at 567 for 1 hr and stored ment activation and immune complexes to be captured
on the surface of rsCR1-coated wells. Noncaptured virusat 0707 until use. Healthy, noninfected individuals were
recruited from local research laboratories. Vaccinated was removed by washing the wells three times with 200
ml of phosphate-buffered saline, pH 7.4 (PBS), each time.volunteers were immunized with a recombinant vaccinia
virus containing the entire coding sequence for the HIV- The final PBS wash was aspirated and captured virus
disrupted in 100 ml of 0.5% Triton X-100 and quantified1 IIIB gp160 (HIVAC-1e, Oncogen/Bristol-Myers Squibb,
Seattle, WA) and were boosted with 640 mg of purified by p24 immunoassay. Concentration of HIV-1 p24 was
determined from a standard curve using reagents pro-rgp160IIIB subunit (VaxSyn, MicroGeneSys, Inc., Meridan,
CT). Sera were obtained 2 weeks before boosting (visit vided in the kit. Basic principles of the CR1-IC assay are
illustrated in Fig. 1.13) and 2 weeks after boosting (visit 15). Details of the
vaccine study design and relevant immune responses CR1-captured virus was shown to be infectious by per-
forming assays as described above except that Triton X-generated have been published previously (Graham et
al., 1993, 1994; Montefiori et al., 1992a, 1993a). HIV-1- 100 was omitted and MT-2 cells (5 1 104 cells in 200 ml
of growth medium) were added to each well and allowedinfected individuals were recruited from patients at-
tending Duke University Medical Center and were con- to incubate for 3 hr at 377 in a humidified chamber. Cells
were transferred to fresh 96-well culture plates (Costar,firmed to be HIV-1 positive by Western immunoblot (Du
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FIG. 1. Principles of the CR1-IC assay. Immune complexes are formed in vitro by incubating virus, antibodies, and fresh normal human serum
as a source of complement. Immune complexes are subsequently captured on the surface of 96-well immunoplates coated with rsCR1 and detected
by p24 immunoassay or by infection of CD4/ lymphocytes.
Cambridge, MA) and incubated for 5 days. Infection was levels of detection with this serum were obtained with the
highest concentration of unput virus we could achieve.quantified by p24 immunoassay performed with 25 ml of
cell suspensions that had been mixed with 475 ml of 0.5% A requirement for complement was determined by in-
cubating HIV-1 IIIB and MN with sera from four infectedTriton X-100.
individuals in the presence of: (1) fresh normal human
Statistical analysis serum as a source of complement, (2) normal human
serum that had been heat-inactivated to destroy comple-The relationship between the magnitude and titer of
ment, and (3) normal human serum depleted of comple-CR1-IC activity in sera HIV-1-infected individuals, and
ment component C3. Virus captured by immobilizedthe titers of CR1-IC activity between nonprogressors and
rsCR1 was greatly reduced with heat-inactivated and C3-progressors were assessed by the Wilcoxon signed rank
depleted serum in all cases (Table 1), confirming thattest using two-tailed analysis. HIV-1 p24 values 100
HIV-1 detection in the CR1-IC assays requires comple-pg/ml were assigned a value of 100 pg/ml and titers50
ment.were assigned a value of 25 for analyses. P values0.05
were considered moderately significant but strongly sig-
HIV-1 immune complexes captured by rsCR1 arenificant when 0.01.
infectious
RESULTS HIV-1 immune complexes captured by immobilized
rsCR1 were shown to be infectious by performing theConditions for HIV-1 immune complex capture
CR1-IC assay with HIV-1 IIIB and sera from three infected
Optimum conditions for virus capture in the CR1-IC individuals, and adding MT-2 cells as targets for infec-
assay were determined by coating wells with rsCR1 con- tion. A separate set of reactions was run in parallel to
centrations of 0, 0.2, 2, and 20 mg/ml. Three concentra- determine the amount of captured virus that was present
tions of HIV-1 IIIB and MN incubated with fresh normal before MT-2 cells were added. In all three cases, a much
human serum as a source of complement, and 1:100- higher level of p24 was present 5 days after the addition
diluted serum from an infected individual, were used at of MT-2 cells (Table 2). This could only have occurred if
each rsCR1 concentration. No HIV-1 p24 was detected virus replication had taken place. Little or no replicated
in noncoated wells or when serum from the infected virus was detected when heat-inactivated complement
person was tested without the addition of exogenous serum was used or when antibodies were absent, indi-
virus (data not shown). The quantity of p24 detected in- cating a requirement for complement and antibody.
creased as the concentration of rsCR1 was increased
up to 2 mg/ml, with no additional increase seen at 20 Frequent detection of CR1-IC activity using HIV-1 IIIB
mg/ml (Fig. 2A). The optimum concentration of rsCR1 was and sera from infected individuals
therefore determined to be approximately 2 mg/ml, which
was used for all further assays. The results in Table 1 indicate that CR1-IC activity
measured with HIV-1 IIIB and MN was highly prevalentThe linear range of virus detection was determined by
adding increasing concentrations of IIIB and MN using for sera from HIV-1-infected individuals. The prevalence
and titer of IIIB-specific CR1-IC activity were examinedrsCR1 at 2 mg/ml, and 1:100-diluted serum from an in-
fected individual. Virus was reliably detected when as further using sera from an additional 14 infected individu-
als who were nonprogressors (CD4 600/mm3) and 10little as 0.5 ng p24 was added, which is equivalent to a
virus stock containing 10 ng p24/ml. Higher concentra- individuals who were progressors (CD4 380/mm3) (Ta-
ble 3). CR1-IC activity was detected with most sera andtions of input virus permitted better detection, where the
amount of HIV-1 immune complexes captured by rsCR1 titers ranged from 50 to 12,150. Magnitudes of activity
(i.e., amount of HIV-1 captured in pg p24/ml) at the lowestincreased linearly up to at least 175 pg p24/ml/well for
IIIB and 140 pg p24/ml/well for MN (Fig. 2B). Maximum serum dilution tested (1:50) correlated with the titer,
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FIG. 2. Conditions for HIV-1 immune complex capture. CR1-IC assays were performed with HIV-1 IIIB and MN incubated with 1:4-diluted fresh
normal human serum as a source of complement, and 1:100-diluted serum from an HIV-1-positive nonprogressor as a source of antibody. Results
are plotted as the quantity of HIV-1 immune complexes captured with increasing concentrations of rsCR1 (A), and the quantity of HIV-1 immune
complexes captured as the concentration of input virus is increased using wells coated with rsCR1 at 2 mg/ml (B). HIV-1 IIIB was used at 5.6 ng
p24/assay (solid circle), 2.8 ng p24/assay (solid triangle), and 1.4 ng p24/assay (solid square). HIV-1 MN was used at 2.0 ng p24/assay (solid circle),
1.0 ng p24/assay (solid triangle), and 0.5 ng p24/assay (solid square). Values of captured virus are plotted as the average of duplicate assays.
where samples with higher titers had more virus cap- Type-specific reactivity in sera from vaccinated
tured by a 1:50 serum dilution (P  .0002). Based on volunteers
average titers, sera from progressors were moderately
less reactive than sera from nonprogressors (P  .044). Sera from vaccinated volunteers were evaluated in
No HIV-1 p24 was detected in any sera without adding CR1-IC assays with HIV-1 MN, IIIB, and primary isolate
exogenous virus (data not shown). This latter observation 101B. Sera from four infected individuals and from four
indicates that the assay detected HIV-1 immune com- HIV-1-naive individuals were evaluated as controls; no
plexes formed exclusively in vitro. In addition, assays clinical information was available for these infected indi-
performed more than once on separate days under iden- viduals. The results are shown in Table 4. Sera from
tical conditions yielded similar results, indicating that the HIV-1-naive individuals were negative with all three virus
assay is highly reproducible. variants, which shows that complement alone was not
sufficient for detection in this assay without the addition
of antibody. The addition of sera from infected individualsTABLE 1
gave positive results for each virus variant, including pri-
Complement Requirement for HIV-1 Immune Complex Detection in
mary isolate 101B. Sera from vaccinees produced littlethe CR1-1C Assay
or no detection of any virus variant prior to subunit boost-
Virus captured (pg p24/ml) in human serum that is:a ing (visit 13) but sera from four of five vaccinees obtained
postboosting (visit 15) were strongly positive with IIIB.
Virusb Fresh Heat inactivated C3-Deficient This vaccine-induced response is consistent with the
boosting effect seen for binding and neutralizing antibod-IIIB 236 { 90 17 { 6 15 { 6
ies in sera from these vaccinated volunteers (Graham etMN 158 { 37 6 6
al., 1993, 1994; Montefiori et al., 1993a) and agrees with
a Assays were performed in duplicate with a 1:25 dilution of sera results obtained with CR1-positive K562 cells (Montefiori
from four infected individuals. Values represent the average of dupli-
et al., 1994). A marginal increase in positive reactivity tocate values for all four samples { standard deviation.
MN and primary isolate 101B was observed for serab Viruses were present at 11 ng p24/assay (IIIB) and 16 ng p24/assay
(MN). obtained postboosting, but this level was much lower
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TABLE 2 CR1-IC activity against primary isolates using
autologous seraVirus Captured in the CR1-IC Assay Is Infectious and Transferable
to CD4/ Lymphocytes Sera from seven HIV-1-infected individuals were as-
sessed for CR1-IC activity against the respective autolo-Quantity of virus (pg p24/ml)
gous isolate obtained at the time of serum collectioncaptured in wells or replicated
in MT-2 cells:a (Fig. 3). In order to optimize detection the assays were
performed with the highest concentration of input virus
Serumb Conditions Capture Replication achievable. Compared to the quantity of p24 detected in
the presence of complement alone, antibody-mediatedPBS C* 4 { 1 73 { 19
CR1-IC activity was observed in only three cases (i.e.,HA-C* 6 { 4 3
M35064, P59423, and W35323). The magnitude of anti-
D75899 C* 234 { 40 1797 { 2226
body-mediated CR1-IC activity in these three cases wasHA-C* 59 { 76 3
considerably low. Complement alone produced a rela-
C78104 C* 266 { 66 838 { 1208 tively high level of activity with isolate W44991, and the
HA-C* 8 { 1 3
addition of antibody had no further effect. The greater
W25798 C* 169 { 27 4928 { 2487 quantity of p24 detected with W44991 may be due to
HA-C* 7 { 1 3 the higher amount of virus added to the assay (9.5 ng)
compared to IIIB, MN, and other isolates. Overall, thesea HIV-1 IIIB (equivalent to 7.5 ng p24/assay) was incubated with
results indicate that little or no CR1-IC activity is detectedantibodies and either fresh normal human serum as a source of com-
plement (C*) or the same normal human serum after it had been heat- with primary isolates using the autologous serum ob-
inactivated to destroy complement (HA)-C*). Virus was quantified by tained at the time of virus isolation.
p24 immunoassay before (capture) or 5 days after the addition of MT-
2 cells (replication).
DISCUSSIONb Serum samples were evaluated at a 1:40 dilution in two sets of
triplicate wells. MT-2 cells were added to one set of triplicate wells
We previously determined that HIV-1 IIIB binds to CR1after binding were complete and unbound virus was washed-out as
on cell surfaces in the presence of envelope-specificdescribed under Materials and Methods.
antibodies and complement (Montefiori et al., 1994). This
observation was confirmed and extended here using an
assay which detects HIV-1 immune complexes capturedthan that for IIIB reactivity. One exception was found
for volunteer A20, whose postboost serum was strongly by immobilized rsCR1 (CR1-IC assay). Immobilized rsCR1
behaved much like cell-surface CR1 by requiring comple-reactive with the primary isolate.
TABLE 3
CR1-IC Activity against HIV-1 IIIB in Sera from HIV-1-Infected Individuals
CR1-IC Activity a CR1-IC Activity a
Nonprogressor Magnitude Titer Progressor Magnitude Titer
100 100 450 P59423 39 50
101 100 1,350 W25798 100 1350
102 72 450 V89872 43 1350
103 49 450 V67970 6 50
104 14 50 W179273 8 50
105 32 450 W86165 6 50
106 100 12,150 M35064 7 50
107 44 450 W08684 100 1350
108 29 nt W35323 27 450
109 98 4,050 W44991 6 50
110 72 450
111 22 450
112 63 4,050
113 100 12,150
Average 2,842 { 4,342 475 { 617
a CR1-IC was measured with HIV-1 IIIB (4 ng p24/assay). Serum samples were assayed in duplicate at three-fold dilutions ranging from 1:50 to
1:109,350. Values are the amount of virus (pg p24/ml) captured on the surface of CR1-coated wells using a 1:50 serum dilution (magnitude), and
the reciprocal of the last dilution where a detectable amount of virus was captured (titer). nt, not tested.
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TABLE 4 could at least partially explain the rapid clearance of
plasma virus, where the plasma half-life of HIV-1 hasCR1-IC Activity in Sera from Infected Individuals
been estimated to be 2 days or less and to have a turn-and gp160-Vaccinated Volunteers
over rate of approximately 6.8 1 108 plasma virions per
CR1-IC Activity witha day (Ho et al., 1995; Wei et al., 1995; Perelson et al.,
1996). In addition to controlling plasma viremia during
Serumb Visit MN IIIB 101B
infection, complement-activating antibodies induced by
vaccination and which target HIV-1 to CR1 could poten-Seronegatives
A nac 6 6 6 tially provide some level of protection from infection.
M na 6 6 6 Complement-activating antibodies might also contrib-
Rh na 6 6 6 ute to the retention of virus in lymphoid organs. Comple-
Ru na 6 6 6
ment and antibody have been shown to trap HIV-1 on
Infected individuals the surface of FDC (Joling et al., 1993), which express a
S69160 na 33 90 47 high density of CR1 (Reynes et al., 1985), and where the
S68030 na 100 100 100
trapped virus could serve as a important source of anti-T00953 na 100 100 45
gen for immune reponses (Pantaleo et al., 1994). LessS23076 na 100 100 100
desirable outcomes also seem possible. For example,
Vaccinees (HIVAC-1e /
although trapped virus does not lead to productive infec-IIIB rgp160)
tion of FDC prior to the onset of AIDS (Schmitz et al.,A1 13 10 6 ntd
A1 15 14 6 6 1994), it now appears that it may infect CD4/ lympho-
cytes and contribute to virus spread (Heath et al., 1995).A17 13 6 6 nt
This is consistent with our observation that HIV-1 im-A17 15 25 46 13
mune complexes captured by solid-phase rsCR1 can be
A20 13 14 6 nt
transferred to MT-2 cells for productive infection. TheA20 15 23 100 100
possibility that CR1 serves as a direct port of entry in
A22 13 6 6 nt certain cell types (Thieblemont et al., 1993a; Delibrias et
A22 15 16 100 32
al., 1994) may also be reflected by antibodies measured
A28 13 6 6 nt in this model.
A28 15 10 100 27 Several lines of evidence support a role for comple-
ment in the pathogenesis of HIV-1 infection. For example,a Virus concentrations were 4 ng p24/assay (MN), 3 ng p24/assay
complement is chronically activated in many infected in-(IIIB), and 2 ng p24/assay (101B). Values are the amount of virus (pg
p24/ml) captured on the surface of CR1-coated wells. dividuals (Perricone et al., 1987; Senaldi et al., 1990), and
b Sera were evaluated at a 1:50 dilution. immune complexes containing complement, immuno-
c na, not applicable.
d nt, not tested due to limited supply of sample.
ment and antibody for virus capture and by producing
results similar to those obtained with CR1-positive K562
cells when sera from vaccinated volunteers were evalu-
ated. The fact that sera from these vaccinated volunteers
contain only envelope-specific antibodies to HIV-1 (Gra-
ham et al., 1993, 1994) indicates that the immune com-
plexes detected by p24 immunoassay consisted of whole
virus and were not merely virus-free p24 complexed with
antibody and complement. Additional evidence for the
presence of whole virus came from the demonstration
that captured immune complexes were infectious
(Table 2).
Complement-activating antibodies that target HIV-1 FIG. 3. Autologous CR1-IC activity against primary isolates. Sera
immune complexes to CR1-bearing cells in vivo could from seven HIV-1-infected individuals were tested at a 1:50 dilution for
CR1-IC activity against the autologous virus isolated at the time ofhave multiple consequences. For example, attachment
serum collection. The amount of virus used per assay was 2.6 ng forto CR1 on RBC is likely to promote the clearance of
M35064, 1.7 ng for C78104, 9.5 ng for W44991, 3.0 ng for V89872, 5.1plasma virus much the same as it clears other particulate
ng for P59423, 4.1 ng for W08684, and 3.4 ng for W35323. Assays were
antigens from the circulation (Nelson, 1953; Cornacoff et performed with complement alone (open bars) and with complement
al., 1983; Ross and Medof, 1985; Herbert and Cosio, 1987; plus test serum (closed bars). Values are the average of triplicate
assays with error bars indicating standard deviation.Rosse, 1987; Schifferli et al., 1988). This phenomenon
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globulin, and infectious virus have been identified in their autologous sera were used (Fig. 3). All of the primary
isolates and autologous sera used in this evaluationperipheral blood (Morrow et al., 1986; Fiscus et al., 1993;
Kobayashi et al., 1993). A role for CR1 is further indicated came from HIV-1-infected progressors but we can draw
no conclusions regarding disease progression since iso-by evidence that CR1 expression on RBC decreases as
circulating immune complexes increase during later lates and autologous sera from nonprogressors were
not studied. Additional studies with sequential primarystages of infection (Inada et al., 1986; Jouvin et al., 1987;
Tausk et al., 1986). These observations indicate that the isolates and autologous sera obtained at different stages
of HIV-1 infection may eventually determine the naturestudy of complement-activating antibodies that target
HIV-1 immune complexes to CR1 could provide new in- and extent of natural variation in CR1-IC epitopes and
the impact of CR1-IC antibodies on HIV-1 pathogenesis.sights into the mechanisms of HIV-1 pathogenesis and
immunity. While this assay may prove useful in assessing relative
levels of CR1-IC antibodies as a correlate of immunity,CR1-IC antibodies reactive with HIV-1 IIIB were highly
prevalent in sera from infected individuals, and the titers it should be noted that detection required high levels of
input virus and that the fraction of virus captured in thewere marginally higher in sera from nonprogressors
compared to progressors (Table 3). This may be taken as assay was considerably small. For example, we never
detected more than 5% of the total amount of input viralevidence that levels of HIV-1-specific CR1-IC antibodies
decrease at later stages of infection. Additional results p24 used in assays. The small fraction of virus that is
captured may be an indication that relatively few virusshowed that sera from infected individuals also react
well with HIV-1 MN (Tables 1 and 4) and a primary isolate particles are targets for the antibodies we were measur-
ing. Even so, our results that show infectious virus is(Table 4). CR1-IC antibodies induced by vaccination were
by comparison highly specific for the vaccine strain of targeted (Table 2) indicate that measurements in the
CR1-IC assay could be relevant to pathogenesis. An al-virus, a result which indicates that complement-activat-
ing antibodies to HIV-1 envelope glycoproteins can ex- ternative explanation for the small fraction of virus cap-
tured is afforded by the recent observation that Factor Hhibit a certain degree of type-specificity. Some of this
specificity is probably explained by sequence diversity binds the envelope gp120 of HIV-1 (Pinter et al., 1995)
and participates in the interaction of cell-free HIV-1 withwithin relevant epitopes, but other antibodies induced by
this vaccine would be expected to bind conserved re- complement (Stoiber et al., 1996). In addition to its nega-
tive control of C3b,Bb convertase, Factor H is an essen-gions of the envelope glycoproteins and produce broader
reactivity. In fact, IgG1 and IgG3, both of which are capa- tial cofactor for the Factor I-mediated degradation of sur-
face-bound C3b, destroying the ability of C3b to bindble of complement activation (Schumaker et al., 1976;
Spiegelberg, 1974), are the most prevalent immunoglobu- CR1 (Ross and Medoff, 1985). Hence, in addition making
relative measurements of HIV-1-specific CR1-IC antibod-lins induced by this vaccine (Montefiori et al., 1992a)
and are dominant immunoglobulins induced by HIV-1 ies, this assay may be useful for studying the regulation
of complement utilization by HIV-1 and for assessinginfection (Khalife et al., 1988; Klasse and Blomberg, 1987;
Sundquist et al., 1986). In these cases complement acti- whether the extent to which the virus is targeted to CR1
is sufficient to have an impact on pathogenesis.vation might be blocked by the molecular environment
of epitopes on the envelope glycoproteins of HIV-1. For
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